罗博特科 reported revenue of ¥0.61B for the period ended 2026-06-30, +144.8% year on year. Net income was ¥0.01B, a 1.0% net margin on a 41.6% gross margin. The largest revenue line is 斐控分部 at 85% of the total. Free cash flow for the period was ¥0.21B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.61B | +144.8% |
| Gross profit | ¥0.25B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | — |
| Gross margin | 41.6% | Net margin 1.0% |
| Revenue Q/Q | +171.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 斐控分部 | ¥0.52B | 84.8% |
| 罗博分部 | ¥0.26B | 42.4% |
| 分部间抵销 | ¥-0.17B | -27.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.36B | 58.4% |
| R&D | ¥0.08B | 12.8% |
| SG&A | ¥0.12B | 20.0% |
| Tax & other | ¥0.00B | 0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥3.89B |
| Total liabilities | ¥2.23B |
| Shareholders' equity | ¥1.66B |
| Equity / assets | 42.7% |
| Operating cash flow | ¥0.24B |
| Capital expenditure | ¥0.03B |
| Free cash flow | ¥0.21B |
| Cash conversion (OCF / net income) | 3722% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
七彩化学 ・ 康龙化成 ・ 立华股份 ・ 上海瀚讯 ・ 锦浪科技 ・ 石药创新 ・ 每日互动 ・ 震安科技 ・ 迪普科技 ・ 德方纳米 ・ 新媒股份 ・ 智莱科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies